We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 13 for:    "ornithine transcarbamylase deficiency"
Previous Study | Return to List | Next Study

Investigation of Brain Nitrogen in Partial Ornithine Transcarbamylase Deficiency (OTCD) Using 1 H MRS, DTI, and fMRI

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01569568
First Posted: April 3, 2012
Last Update Posted: April 14, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Children's Research Institute
Information provided by (Responsible Party):
Andrea Gropman, Children's Research Institute
March 30, 2012
April 3, 2012
June 30, 2015
April 14, 2017
April 14, 2017
September 2010
August 2014   (Final data collection date for primary outcome measure)
  • Concentration of Glutamine and Myoinositol [ Time Frame: Baseline ]

    Concentration based on area under curve on 1H Magnetic Resonance Spectroscopy(MRS) and quantitated by LCModel (a method that allows automatic quantitation of spectroscopy data). A metabolite's tissue concentration is related to the integrated amplitude, the area under the curve of the MRS signal, it produces. While MRS signals are usually acquired in the time domain as free induction decays or echoes, they are usually viewed and analyzed in the frequency domain. The frequency domain representation is derived from the acquired time domain data by the Fourier Transform. The protocol we use selects 257 averages. The machine summates the data at each time point to generate one value for the area under the curve. Therefore, we don't have the measurement at each time point.

    Furthermore, we measured voxels in two different brain areas containing different kinds of brain matter: one voxel was located in posterior cingulate gray matter (PCGM) and the other in parietal white matter (PWM).

  • Functional Connectivity of Assessed by Resting-state fMRI [ Time Frame: Baseline ]
    Investigation of differences in functional connectivity of OTCD patients compared to healthy controls, particularly in the default-mode network (DMN) and the set-maintenance network (SMN). Participants underwent a resting-state scan using 3T fMRI. Combining independent component analysis (ICA) and region-of-interest (ROI) analyses, identified the nodes that comprised each network in each group, and assessed internodal connectivity. For each subject, this analysis generated a correlation value, which reflected the strength of functional connectivity between each ROI pair.The correlation r-values were normalized using Fisher's r-to-Z-transform, generating z-scores. The DMN was composed of 1) anterior cingulate/medial prefrontal cortex (ACC/mPFC), 2) posterior cingulate cortex (PCC), and 3) bilateral inferior parietal lobule (IPL). The SMN was composed of 1)ACC, 2) bilateral superior frontal gyrus (SFG), and 3) bilateral anterior insula/frontal operculum (aI/fO).
  • Fractional Anisotropy Assessed Using DTI [ Time Frame: Baseline ]
    Fractional Anisotropy (FA) is a measure of the diffusion asymmetry within a voxel as defined by its eigenvalues. In our study, FA is being used as a measure of white matter integrity, because FA is very sensitive to small microstructural changes.Fractional anisotropy (FA) is a scalar value between zero and one (0-1) that describe anisotropy of a diffusion process. A value of zero means that diffusion is isotropic, i.e. it is unrestricted (or equally restricted) in all directions. A value of one means that diffusion occurs only along one axis and is fully restricted along all other directions.
Biomarker characterization [ Time Frame: Baseline ]
To characterize metabolic, structural and cognitive changes in OTCD by 1H MRS, DTI, volumetric measures, and fMRI and to validate biomarkers for the effect of HA and its treatment on the brain.
Complete list of historical versions of study NCT01569568 on ClinicalTrials.gov Archive Site
Neuropsychological Assessment [ Time Frame: Baseline ]
Testing consisted of the Wechsler Abbreviated Scale of Intelligence (WASI), Comprehensive Trail Making Test (CTMT) (range 17-87), and the Behavioral Rating Inventory of Executive Function (BRIEF) (range GEC: 70-210; BRI:39-82 ; MI:41-92). The WASI includes three measures of intelligence; including, performance IQ (sum of block design and matrices sub scales; range: 40-160), verbal IQ (sum of vocabulary and similarities sub scales; range 40-160), and total IQ (sum of all four subscales; range: 80-320). The CTMT measures simple attention and executive function, it consists of five dot to dots that increase with complexity and difficulty. Higher values indicate better outcomes for all scales.
Correlation of imaging markers with cognitive function [ Time Frame: Baseline ]
To correlate the findings from neuroimaging with cognitive functioning and clinical parameters.
Not Provided
Not Provided
 
Investigation of Brain Nitrogen in Partial Ornithine Transcarbamylase Deficiency (OTCD) Using 1 H MRS, DTI, and fMRI
Investigation of Brain Nitrogen in Partial Ornithine Transcarbamylase Deficiency (OTCD) Using 1 H MRS, DTI, and fMRI
The purpose of this study is to use various types of MRI and cognitive testing to evaluate changes in the brain and cognitive function that occur in subjects with ornithine transcarbamylase deficiency (OTCD) relative to healthy individuals

The overall goal of this project is to characterize metabolic, structural and cognitive changes in OTCD using 1H MRS, DTI, volumetric averaging and fMRI with cognitive testing of executive function measures to validate biomarkers for the effect of HA and its treatment on the brain.

The investigators will measure gln and mI in blood and brain (using 1H MRS) in affected participants, and mI in brain in controls, fractional anisotropy as a measure of white matter microstructural damage (by DTI) and brain activation pathways alterations with tasks probing working memory (fMRI). As a secondary outcome measure, the investigators will correlate the findings from neuroimaging with cognitive functioning. This protocol is based on the previous 5104 protocol, now includes children to evaluate the age and stage of disease on these indices in a cohort that is undergoing important developmental events against an age matched typically developing cohort.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Males and females, ages 7-60 years with ornithine transcarbamylase deficiency Males and females, ages 7-60 years who are healthy controls without ornithine transcarbamylase deficiency
Ornithine Transcarbamylase Deficiency
  • Other: MRI scanning
    1H MRS, DTI, FMRI
    Other Name: MRI
  • Behavioral: Cognitive testing
    Behavioral testing
  • Subjects with OTCD

    males and females ages 7-60 years with OTCD who are able to undergo MRI and cognitive testing MRI scanning

    1H MRS, DTI, FMRI Cognitive testing Neuropsychological testing

    Interventions:
    • Other: MRI scanning
    • Behavioral: Cognitive testing
  • Healthy controls

    males and females ages 7-60 years who are healthy controls who are able to undergo MRI and cognitive testing MRI scanning

    1H MRS, DTI, FMRI Cognitive testing Neuropsychological testing

    Interventions:
    • Other: MRI scanning
    • Behavioral: Cognitive testing

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
49
August 2014
August 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Subject inclusion criteria:

  1. Patients with OTCD;
  2. Age range: 7-60 years
  3. Able to undergo neuroimaging safely (i.e. without presence of ferromagnetic devices)
  4. Subject has a documented full scale IQ > 70

Control participant inclusion criteria:

  1. Healthy males and females without metabolic disease aged 7-60 years
  2. Subject has a documented full scale IQ > 70

Exclusion Criteria:

Subject exclusion criteria:

  1. Mental retardation (i.e., Full Scale IQ< 70)
  2. Age range <7 or >60 years
  3. Presence of ferromagnetic device(s) that preclude safe imaging
  4. Pregnant female

Control exclusion criteria:

  1. Subjects with a documented history of an intellectual deficit (i.e., Full Scale IQ< 70)
  2. Age range <7 or >60 years
  3. Presence of ferromagnetic device(s) that preclude safe imaging
  4. Pregnant female
Sexes Eligible for Study: All
7 Years to 60 Years   (Child, Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
 
NCT01569568
UCRDC 5107
Yes
Not Provided
Plan to Share IPD: Yes
Plan Description: Final data is on the UCDC website
Andrea Gropman, Children's Research Institute
Andrea Gropman
Children's Research Institute
Principal Investigator: Andrea L Gropman, M.D. Children's Research Institute
Children's Research Institute
April 2017